<DOC>
	<DOCNO>NCT01029275</DOCNO>
	<brief_summary>The aim study evaluate interest six month pre-operative treatment long-acting somatostatin analog ( Sandostatin LP ) versus surgery alone patient pituitary adenoma responsible acromegaly .</brief_summary>
	<brief_title>Somatostatin Analog Treatment Acromegaly Before Pituitary Surgery : Comparison With Neurosurgery Alone</brief_title>
	<detailed_description>Somatotroph pituitary adenoma frequent cause acromegaly . A transsphenoidal removal tumor use first line treatment . Somatostatin analog use whether recovery obtain surgery pituitary surgery contraindicate . Previous study somatostatin analog show drop plasma GH IGF-1 level reduction adenoma size 75 25 % patient respectively . Retrospective study suggest treatment somatostatin analog perform surgery may interest improve anesthesic condition surgical outcome . The aim present study prospectively evaluate interest first line treatment long-acting somatostatin analog ( Sandostatin ) perform pituitary surgery acromegalic patient either micro macroadenoma improve peri-operative condition hopefully surgical outcome . After informed consent , untreated acromegalic patient include randomly assign one follow treatment procedure : either pituitary surgery six month treatment long-acting Sandostatin 30 mg monthly 6 month perform transsphenoïdal adenoma removal . The patient evaluate treatment , month 3 6 treatment Sandostatin ( patient enrol arm study ) month 3 12 pituitary neurosurgery . Each evaluation include clinical data , hormone test radiological ( MRI ) investigation . The main endpoint rate recovery prove normalisation GH secretion plasma IGF-1 level . Secondary endpoint include evaluation clinical , radiological , biological , anesthesic , surgical pathological parameter . A comparison two arm perform entry study , time surgery month 3 12 follow transsphenoidal removal somatotroph adenoma .</detailed_description>
	<mesh_term>Acromegaly</mesh_term>
	<mesh_term>Pituitary Diseases</mesh_term>
	<mesh_term>Pituitary Neoplasms</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>men woman 1880 year old untreated acromegaly unsuppressed GH secretion glucose load elevate IGF1 plasma level presence pituitary adenoma MRI inform consent give . acromegaly previously treat contraindication pituitary surgery associate hyperprolactinemia 200 ng/ml visual field defect need rapid transsphenoidal surgery contraindication treatment octreotide</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Acromegaly</keyword>
	<keyword>pituitary adenoma</keyword>
	<keyword>octreotide</keyword>
	<keyword>transsphenoïdal surgery</keyword>
	<keyword>GH</keyword>
	<keyword>IGF-1</keyword>
</DOC>